Actively Recruiting
Evaluating 177LuLu-DOTA-TATE Combined with Octreotide LAR Versus Octreotide LAR Alone in Patients Aged 12 and Older With Advanced Grade 1 and 2 Gastroenteropancreatic Neuroendocrine Tumors
Led by Novartis Pharmaceuticals · Updated on 2026-09-11
240
Participants Needed
67
Research Sites
267 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients aged 12 and older with newly diagnosed, advanced gastroenteropancreatic neuroendocrine tumors GEP-NETs that are somatostatin receptor positive and well differentiated Grade 1 or Grade 2 with a Ki-67 index less than 10%. The study aims to compare the effectiveness and safety of a combination treatment of 177LuLu-DOTA-TATE plus octreotide long-acting release LAR against octreotide LAR alone in patients with a high disease burden. Participants are randomly assigned to receive either four doses of 177LuLu-DOTA-TATE administered every eight weeks combined with octreotide LAR given every eight weeks followed by every four weeks, or octreotide LAR alone given every four weeks. The study includes a screening phase, a treatment phase where the interventions are administered, and a follow-up phase to monitor outcomes. During the study, participants undergo multiple assessments including imaging to confirm tumor receptor status, laboratory tests to monitor organ function, and evaluations of tumor progression and response. Researchers also assess quality of life and pharmacokinetics of the study drug. The primary outcome is progression-free survival measured by a blinded independent review committee, with follow-up planned up to 60 months after randomization to evaluate overall survival and other secondary outcomes.
CONDITIONS
Brief Title
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here